Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse
Differentiation of active disease from fibrosis/mature teratoma in patients with residual masses or identifying of sites of recurrence in patients with raised markers following treatment of their testicular cancer remains a problem. 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) has...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2000-10, Vol.83 (7), p.863-869 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 869 |
|---|---|
| container_issue | 7 |
| container_start_page | 863 |
| container_title | British journal of cancer |
| container_volume | 83 |
| creator | Hain, S F O'Doherty, M J Timothy, A R Leslie, M D Harper, P G Huddart, R A |
| description | Differentiation of active disease from fibrosis/mature teratoma in patients with residual masses or identifying of sites of recurrence in patients with raised markers following treatment of their testicular cancer remains a problem.
18
F-fluorodeoxyglucose positron emission tomography (FDG-PET) has the potential to identify active disease and thereby influence further management in these patients. We performed a retrospective study of the use of FDG-PET in detecting residual/recurrent testicular carcinoma in 55 patients (seventy FDG-PET scans). Forty-seven scans were for the assessment of residual masses (18 had raised markers) and 23 scans were for the investigation of raised markers in the presence of normal CT scans. True positive results were based on positive histology or clinical follow-up. FDG-PET had a positive predictive value (PPV) of 96% and a negative predictive value (NPV) of 90% in patients with residual masses. This PPV was equivalent to that of markers (94%) but FDG-PET had the advantage of identifying the site of that recurrence. The NPV was higher than that of markers. In patients with raised markers alone the PPV of FDG-PET was 92% but the NPV was only 50%. However, subsequent FDG-PET imaging was frequently the first imaging modality to identify the site of disease. FDG-PET effected a management change in 57% of cases. FDG-PET scanning detected viable tumour in residual masses and identified sites of disease in suspected recurrence. © 2000 Cancer Research Campaign |
| doi_str_mv | 10.1054/bjoc.2000.1389 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2374687</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1019358471</sourcerecordid><originalsourceid>FETCH-LOGICAL-c504t-7216e02f52391e1ef6ef8b168353ade96a17127516b8db5554208c21995f1fb63</originalsourceid><addsrcrecordid>eNp1kc1v1DAQxS0Eokvhyg1kIa7Z2k78dUFCFQWkSlzgbDneyW5WThxsp-r-9zhk1ZYDJ3v8fn4z9kPoLSVbSnhz1R6D2zJCSlkr_QxtKK9ZRRWTz9GmHMuKaEYu0KuUjqXURMmX6IISLYlQYoPsjZ9DDDsI96e9n11IgKeQ-hzDiGHoU-rLJoch7KOdDifcl-oAGO6sn21exNDhPcQBO_Ae53kIc0zYZhzB2ynBa_Sisz7Bm_N6iX7dfPl5_a26_fH1-_Xn28px0uRKMiqAsI6zWlOg0AnoVEuFqnltd6CFpZIyyalo1a7lnDeMKMeo1ryjXSvqS_Rp9Z3mdoCdgzFH680U-8HGkwm2N_8qY38w-3BnWC0boWQx-HA2iOH3DCmbY3nKWGY2jGktVVM3BdqukIshpQjdQwNKzJKIWRIxSyJmSaRceP90rCf4GkEBPp4Bm5z1XbSj69Mj10guxNL4asVSUcby4Y_T_bfzu_XGaPMc4cFRCP1X_wO63q-E</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>229978434</pqid></control><display><type>article</type><title>Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse</title><source>MEDLINE</source><source>Nature</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Hain, S F ; O'Doherty, M J ; Timothy, A R ; Leslie, M D ; Harper, P G ; Huddart, R A</creator><creatorcontrib>Hain, S F ; O'Doherty, M J ; Timothy, A R ; Leslie, M D ; Harper, P G ; Huddart, R A</creatorcontrib><description>Differentiation of active disease from fibrosis/mature teratoma in patients with residual masses or identifying of sites of recurrence in patients with raised markers following treatment of their testicular cancer remains a problem.
18
F-fluorodeoxyglucose positron emission tomography (FDG-PET) has the potential to identify active disease and thereby influence further management in these patients. We performed a retrospective study of the use of FDG-PET in detecting residual/recurrent testicular carcinoma in 55 patients (seventy FDG-PET scans). Forty-seven scans were for the assessment of residual masses (18 had raised markers) and 23 scans were for the investigation of raised markers in the presence of normal CT scans. True positive results were based on positive histology or clinical follow-up. FDG-PET had a positive predictive value (PPV) of 96% and a negative predictive value (NPV) of 90% in patients with residual masses. This PPV was equivalent to that of markers (94%) but FDG-PET had the advantage of identifying the site of that recurrence. The NPV was higher than that of markers. In patients with raised markers alone the PPV of FDG-PET was 92% but the NPV was only 50%. However, subsequent FDG-PET imaging was frequently the first imaging modality to identify the site of disease. FDG-PET effected a management change in 57% of cases. FDG-PET scanning detected viable tumour in residual masses and identified sites of disease in suspected recurrence. © 2000 Cancer Research Campaign</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1054/bjoc.2000.1389</identifier><identifier>PMID: 10970686</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adolescent ; Adult ; alpha-Fetoproteins - metabolism ; Biological and medical sciences ; Biomarkers, Tumor - blood ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Chorionic Gonadotropin, beta Subunit, Human - blood ; Drug Resistance ; Endocrine glands. Genital system. Mammary gland ; Epidemiology ; Fluorine Radioisotopes ; Fluorodeoxyglucose F18 ; Germinoma - blood ; Germinoma - diagnostic imaging ; Germinoma - metabolism ; Humans ; Investigative techniques, diagnostic techniques (general aspects) ; Male ; Medical sciences ; Middle Aged ; Molecular Medicine ; Neoplasm Recurrence, Local - blood ; Neoplasm Recurrence, Local - diagnostic imaging ; Neoplasm Recurrence, Local - metabolism ; Neoplasm, Residual ; Oncology ; Radionuclide investigations ; Radiopharmaceuticals ; Regular ; regular-article ; Retrospective Studies ; Seminoma - blood ; Seminoma - diagnostic imaging ; Seminoma - metabolism ; Sensitivity and Specificity ; Teratoma - blood ; Teratoma - diagnostic imaging ; Teratoma - metabolism ; Testicular Neoplasms - blood ; Testicular Neoplasms - diagnostic imaging ; Testicular Neoplasms - metabolism ; Tomography, Emission-Computed</subject><ispartof>British journal of cancer, 2000-10, Vol.83 (7), p.863-869</ispartof><rights>The Author(s) 2000</rights><rights>2000 INIST-CNRS</rights><rights>Copyright 2000 Cancer Research Campaign.</rights><rights>Copyright Nature Publishing Group Oct 2000</rights><rights>Copyright © 2000 Cancer Research Campaign 2000 Cancer Research Campaign</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c504t-7216e02f52391e1ef6ef8b168353ade96a17127516b8db5554208c21995f1fb63</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374687/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374687/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,2727,27924,27925,41488,42557,51319,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1475664$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10970686$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hain, S F</creatorcontrib><creatorcontrib>O'Doherty, M J</creatorcontrib><creatorcontrib>Timothy, A R</creatorcontrib><creatorcontrib>Leslie, M D</creatorcontrib><creatorcontrib>Harper, P G</creatorcontrib><creatorcontrib>Huddart, R A</creatorcontrib><title>Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Differentiation of active disease from fibrosis/mature teratoma in patients with residual masses or identifying of sites of recurrence in patients with raised markers following treatment of their testicular cancer remains a problem.
18
F-fluorodeoxyglucose positron emission tomography (FDG-PET) has the potential to identify active disease and thereby influence further management in these patients. We performed a retrospective study of the use of FDG-PET in detecting residual/recurrent testicular carcinoma in 55 patients (seventy FDG-PET scans). Forty-seven scans were for the assessment of residual masses (18 had raised markers) and 23 scans were for the investigation of raised markers in the presence of normal CT scans. True positive results were based on positive histology or clinical follow-up. FDG-PET had a positive predictive value (PPV) of 96% and a negative predictive value (NPV) of 90% in patients with residual masses. This PPV was equivalent to that of markers (94%) but FDG-PET had the advantage of identifying the site of that recurrence. The NPV was higher than that of markers. In patients with raised markers alone the PPV of FDG-PET was 92% but the NPV was only 50%. However, subsequent FDG-PET imaging was frequently the first imaging modality to identify the site of disease. FDG-PET effected a management change in 57% of cases. FDG-PET scanning detected viable tumour in residual masses and identified sites of disease in suspected recurrence. © 2000 Cancer Research Campaign</description><subject>Adolescent</subject><subject>Adult</subject><subject>alpha-Fetoproteins - metabolism</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Chorionic Gonadotropin, beta Subunit, Human - blood</subject><subject>Drug Resistance</subject><subject>Endocrine glands. Genital system. Mammary gland</subject><subject>Epidemiology</subject><subject>Fluorine Radioisotopes</subject><subject>Fluorodeoxyglucose F18</subject><subject>Germinoma - blood</subject><subject>Germinoma - diagnostic imaging</subject><subject>Germinoma - metabolism</subject><subject>Humans</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Molecular Medicine</subject><subject>Neoplasm Recurrence, Local - blood</subject><subject>Neoplasm Recurrence, Local - diagnostic imaging</subject><subject>Neoplasm Recurrence, Local - metabolism</subject><subject>Neoplasm, Residual</subject><subject>Oncology</subject><subject>Radionuclide investigations</subject><subject>Radiopharmaceuticals</subject><subject>Regular</subject><subject>regular-article</subject><subject>Retrospective Studies</subject><subject>Seminoma - blood</subject><subject>Seminoma - diagnostic imaging</subject><subject>Seminoma - metabolism</subject><subject>Sensitivity and Specificity</subject><subject>Teratoma - blood</subject><subject>Teratoma - diagnostic imaging</subject><subject>Teratoma - metabolism</subject><subject>Testicular Neoplasms - blood</subject><subject>Testicular Neoplasms - diagnostic imaging</subject><subject>Testicular Neoplasms - metabolism</subject><subject>Tomography, Emission-Computed</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kc1v1DAQxS0Eokvhyg1kIa7Z2k78dUFCFQWkSlzgbDneyW5WThxsp-r-9zhk1ZYDJ3v8fn4z9kPoLSVbSnhz1R6D2zJCSlkr_QxtKK9ZRRWTz9GmHMuKaEYu0KuUjqXURMmX6IISLYlQYoPsjZ9DDDsI96e9n11IgKeQ-hzDiGHoU-rLJoch7KOdDifcl-oAGO6sn21exNDhPcQBO_Ae53kIc0zYZhzB2ynBa_Sisz7Bm_N6iX7dfPl5_a26_fH1-_Xn28px0uRKMiqAsI6zWlOg0AnoVEuFqnltd6CFpZIyyalo1a7lnDeMKMeo1ryjXSvqS_Rp9Z3mdoCdgzFH680U-8HGkwm2N_8qY38w-3BnWC0boWQx-HA2iOH3DCmbY3nKWGY2jGktVVM3BdqukIshpQjdQwNKzJKIWRIxSyJmSaRceP90rCf4GkEBPp4Bm5z1XbSj69Mj10guxNL4asVSUcby4Y_T_bfzu_XGaPMc4cFRCP1X_wO63q-E</recordid><startdate>20001001</startdate><enddate>20001001</enddate><creator>Hain, S F</creator><creator>O'Doherty, M J</creator><creator>Timothy, A R</creator><creator>Leslie, M D</creator><creator>Harper, P G</creator><creator>Huddart, R A</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20001001</creationdate><title>Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse</title><author>Hain, S F ; O'Doherty, M J ; Timothy, A R ; Leslie, M D ; Harper, P G ; Huddart, R A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c504t-7216e02f52391e1ef6ef8b168353ade96a17127516b8db5554208c21995f1fb63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>alpha-Fetoproteins - metabolism</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Chorionic Gonadotropin, beta Subunit, Human - blood</topic><topic>Drug Resistance</topic><topic>Endocrine glands. Genital system. Mammary gland</topic><topic>Epidemiology</topic><topic>Fluorine Radioisotopes</topic><topic>Fluorodeoxyglucose F18</topic><topic>Germinoma - blood</topic><topic>Germinoma - diagnostic imaging</topic><topic>Germinoma - metabolism</topic><topic>Humans</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Molecular Medicine</topic><topic>Neoplasm Recurrence, Local - blood</topic><topic>Neoplasm Recurrence, Local - diagnostic imaging</topic><topic>Neoplasm Recurrence, Local - metabolism</topic><topic>Neoplasm, Residual</topic><topic>Oncology</topic><topic>Radionuclide investigations</topic><topic>Radiopharmaceuticals</topic><topic>Regular</topic><topic>regular-article</topic><topic>Retrospective Studies</topic><topic>Seminoma - blood</topic><topic>Seminoma - diagnostic imaging</topic><topic>Seminoma - metabolism</topic><topic>Sensitivity and Specificity</topic><topic>Teratoma - blood</topic><topic>Teratoma - diagnostic imaging</topic><topic>Teratoma - metabolism</topic><topic>Testicular Neoplasms - blood</topic><topic>Testicular Neoplasms - diagnostic imaging</topic><topic>Testicular Neoplasms - metabolism</topic><topic>Tomography, Emission-Computed</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hain, S F</creatorcontrib><creatorcontrib>O'Doherty, M J</creatorcontrib><creatorcontrib>Timothy, A R</creatorcontrib><creatorcontrib>Leslie, M D</creatorcontrib><creatorcontrib>Harper, P G</creatorcontrib><creatorcontrib>Huddart, R A</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hain, S F</au><au>O'Doherty, M J</au><au>Timothy, A R</au><au>Leslie, M D</au><au>Harper, P G</au><au>Huddart, R A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2000-10-01</date><risdate>2000</risdate><volume>83</volume><issue>7</issue><spage>863</spage><epage>869</epage><pages>863-869</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Differentiation of active disease from fibrosis/mature teratoma in patients with residual masses or identifying of sites of recurrence in patients with raised markers following treatment of their testicular cancer remains a problem.
18
F-fluorodeoxyglucose positron emission tomography (FDG-PET) has the potential to identify active disease and thereby influence further management in these patients. We performed a retrospective study of the use of FDG-PET in detecting residual/recurrent testicular carcinoma in 55 patients (seventy FDG-PET scans). Forty-seven scans were for the assessment of residual masses (18 had raised markers) and 23 scans were for the investigation of raised markers in the presence of normal CT scans. True positive results were based on positive histology or clinical follow-up. FDG-PET had a positive predictive value (PPV) of 96% and a negative predictive value (NPV) of 90% in patients with residual masses. This PPV was equivalent to that of markers (94%) but FDG-PET had the advantage of identifying the site of that recurrence. The NPV was higher than that of markers. In patients with raised markers alone the PPV of FDG-PET was 92% but the NPV was only 50%. However, subsequent FDG-PET imaging was frequently the first imaging modality to identify the site of disease. FDG-PET effected a management change in 57% of cases. FDG-PET scanning detected viable tumour in residual masses and identified sites of disease in suspected recurrence. © 2000 Cancer Research Campaign</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>10970686</pmid><doi>10.1054/bjoc.2000.1389</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2000-10, Vol.83 (7), p.863-869 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2374687 |
| source | MEDLINE; Nature; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; SpringerLink Journals - AutoHoldings |
| subjects | Adolescent Adult alpha-Fetoproteins - metabolism Biological and medical sciences Biomarkers, Tumor - blood Biomedical and Life Sciences Biomedicine Cancer Research Chorionic Gonadotropin, beta Subunit, Human - blood Drug Resistance Endocrine glands. Genital system. Mammary gland Epidemiology Fluorine Radioisotopes Fluorodeoxyglucose F18 Germinoma - blood Germinoma - diagnostic imaging Germinoma - metabolism Humans Investigative techniques, diagnostic techniques (general aspects) Male Medical sciences Middle Aged Molecular Medicine Neoplasm Recurrence, Local - blood Neoplasm Recurrence, Local - diagnostic imaging Neoplasm Recurrence, Local - metabolism Neoplasm, Residual Oncology Radionuclide investigations Radiopharmaceuticals Regular regular-article Retrospective Studies Seminoma - blood Seminoma - diagnostic imaging Seminoma - metabolism Sensitivity and Specificity Teratoma - blood Teratoma - diagnostic imaging Teratoma - metabolism Testicular Neoplasms - blood Testicular Neoplasms - diagnostic imaging Testicular Neoplasms - metabolism Tomography, Emission-Computed |
| title | Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T02%3A04%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fluorodeoxyglucose%20positron%20emission%20tomography%20in%20the%20evaluation%20of%20germ%20cell%20tumours%20at%20relapse&rft.jtitle=British%20journal%20of%20cancer&rft.au=Hain,%20S%20F&rft.date=2000-10-01&rft.volume=83&rft.issue=7&rft.spage=863&rft.epage=869&rft.pages=863-869&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1054/bjoc.2000.1389&rft_dat=%3Cproquest_pubme%3E1019358471%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=229978434&rft_id=info:pmid/10970686&rfr_iscdi=true |